CO6341554A2 - Forma cristalina de (2s)-(-)-n-(6-cloro-2,3-dihidro-benzo(1,4)dioxin-2-ilmetil)-sulfamida. - Google Patents

Forma cristalina de (2s)-(-)-n-(6-cloro-2,3-dihidro-benzo(1,4)dioxin-2-ilmetil)-sulfamida.

Info

Publication number
CO6341554A2
CO6341554A2 CO10163416A CO10163416A CO6341554A2 CO 6341554 A2 CO6341554 A2 CO 6341554A2 CO 10163416 A CO10163416 A CO 10163416A CO 10163416 A CO10163416 A CO 10163416A CO 6341554 A2 CO6341554 A2 CO 6341554A2
Authority
CO
Colombia
Prior art keywords
dioxin
benzo
dihydro
crystalline form
related disorders
Prior art date
Application number
CO10163416A
Other languages
English (en)
Inventor
Steven Mehrman
Wenju Wu
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CO6341554A2 publication Critical patent/CO6341554A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)

Abstract

La presente invención se dirige a una nueva forma cristalina de (2S)-(-)-N-(6-cloro-2,3-dihidro-benzo[1,4) dioxin-2-ilmetil)-sulfamida, composiciones farmacéuticas que contienen dicha forma cristalina y el uso de la forma cristalina en el tratamiento de la ansiedad y trastornos relacionados; depresión bipolar y manía; depresión; epilepsia y trastornos relacionados; epileptogénesis; trastornos relacionados con la glucosa; trastornos relacionados con los lípidos; migraña; obesidad; dolor; abuso de sustancias; o para la neuroprotección. La presente invención se refiere, además, a un proceso para la preparación de la nueva forma cristalina.
CO10163416A 2008-06-23 2010-12-28 Forma cristalina de (2s)-(-)-n-(6-cloro-2,3-dihidro-benzo(1,4)dioxin-2-ilmetil)-sulfamida. CO6341554A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7478308P 2008-06-23 2008-06-23

Publications (1)

Publication Number Publication Date
CO6341554A2 true CO6341554A2 (es) 2011-11-21

Family

ID=41431873

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10163416A CO6341554A2 (es) 2008-06-23 2010-12-28 Forma cristalina de (2s)-(-)-n-(6-cloro-2,3-dihidro-benzo(1,4)dioxin-2-ilmetil)-sulfamida.

Country Status (22)

Country Link
US (1) US8809385B2 (es)
EP (1) EP2340246A2 (es)
JP (1) JP2012530682A (es)
AR (1) AR072961A1 (es)
AU (1) AU2009271362B2 (es)
BR (1) BRPI0915890A2 (es)
CA (1) CA2729056A1 (es)
CL (1) CL2010001540A1 (es)
CO (1) CO6341554A2 (es)
CR (1) CR20110042A (es)
EA (1) EA018567B1 (es)
EC (1) ECSP10010707A (es)
HN (1) HN2010002735A (es)
IL (1) IL210138A0 (es)
MX (1) MX2011000090A (es)
NI (1) NI201000226A (es)
NZ (1) NZ590682A (es)
PE (1) PE20110060A1 (es)
TW (1) TW201012807A (es)
UY (1) UY31934A (es)
WO (1) WO2010008776A2 (es)
ZA (1) ZA201100570B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200612905A (en) * 2004-06-16 2006-05-01 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
CA2578407A1 (en) * 2004-08-24 2006-03-02 Janssen Pharmaceutica N.V. Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents
EP1881959A1 (en) * 2005-05-20 2008-01-30 Janssen Pharmaceutica N.V. Process for preparation of sulfamide derivatives
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US8497298B2 (en) * 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8716231B2 (en) * 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8492431B2 (en) * 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US8937096B2 (en) * 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8691867B2 (en) * 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US20070191474A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
JP2009537635A (ja) * 2006-05-19 2009-10-29 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 癲癇の処置のための共同−療法
US20090247616A1 (en) * 2008-03-26 2009-10-01 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
BRPI0915890A2 (pt) 2008-06-23 2015-11-03 Janssen Pharmaceutica Nv forma cristalina de (2s)-(-)-n-(6-cloro-2,3-di-hidro-benzo[1,4]dioxin-2-ilmetil)-sulfamida
US8815939B2 (en) * 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
JP2014528399A (ja) * 2011-09-29 2014-10-27 ヤンセン ファーマシューティカ エヌ．ベー． スルファミド誘導体の改善された調製プロセス
JP2014528953A (ja) 2011-09-29 2014-10-30 ヤンセン ファーマシューティカ エヌ．ベー． スルファミド誘導体の調製プロセス

Family Cites Families (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US240166A (en) 1881-04-12 Former for shaping corsets
US2527861A (en) 1948-05-07 1950-10-31 Monsanto Chemicals Mono alkyl sulfamides
BE636655A (es) 1962-09-14
DE1211166B (de) 1962-11-20 1966-02-24 Ciba Geigy Verfahren zur Herstellung neuer Sulfamide
US3318952A (en) 1964-01-22 1967-05-09 Sandoz Ag Dibenzylsulfamides
US3320314A (en) 1964-01-22 1967-05-16 Sandoz Ag Chlorobenzyl sulfamides
US3383414A (en) 1964-08-26 1968-05-14 Sandoz Ag Benzocycloalkyl sulfamides
DE1542785A1 (de) 1965-07-24 1970-05-06 Bayer Ag Insekten- und milbenabweisende Mittel
US3539573A (en) 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
US3621096A (en) 1969-04-03 1971-11-16 Univ North Carolina Antidepressant method and composition for same comprising a tricyclic antidepressant and a thyroid hormone
US3606881A (en) 1970-02-20 1971-09-21 Riley D Woodson Conductive rubber electrode
DE2022370A1 (de) 1970-05-08 1971-12-02 Bayer Ag N-Fluordichlormethylthio-sulfamidsaeure-Derivate,Verfahren zu ihrer Herstellung und ihre mikrobizide und fungizide Verwendung
US3829826A (en) 1972-08-22 1974-08-13 Hewlett Packard Co Cable fastener for electrocardiograph electrodes
US5212326A (en) 1979-08-20 1993-05-18 Abbott Laboratories Sodium hydrogen divalproate oligomer
FR2479825A1 (fr) 1980-04-04 1981-10-09 Fabre Sa Pierre Benzodioxanne 1,4 methoxy-2 propanolamines, leur preparation et leur application en tant que medicaments
US4490005A (en) 1982-06-21 1984-12-25 Minnesota Mining And Manufacturing Company Electrical connector
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US4804663A (en) 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
IE58370B1 (en) 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
US4635642A (en) 1985-07-18 1987-01-13 American Hospital Supply Corporation Medical electrode with reusable conductor
GB8607684D0 (en) 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5158952A (en) 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
GB8908085D0 (en) 1989-04-11 1989-05-24 Lundbeck & Co As H New therapeutic use
US5238945A (en) 1989-04-11 1993-08-24 H. Lundbeck A/S Method of treating psychoses
US5194446A (en) 1989-06-12 1993-03-16 A. H. Robins Company, Incorporated Compounds having one or more aminosulfaonyloxy radicals useful as pharmaceuticals
US5273993A (en) 1989-06-12 1993-12-28 A. H. Robins Company, Incorporated Compounds having one or more aminosulfonyloxy radicals useful as pharmaceuticals
US5192785A (en) 1989-09-03 1993-03-09 A. H. Robins Company, Incorporated Sulfamates as antiglaucoma agents
US5229382A (en) 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5189179A (en) 1990-08-29 1993-02-23 Merrell Dow Pharmaceuticals Inc. Serotonin 5ht1a agonists
AU641052B2 (en) 1990-11-02 1993-09-09 Aventisub Ii Inc. 3-amidoindolyl derivatives
GB9026998D0 (en) 1990-12-12 1991-01-30 Glaxo Group Ltd Medicaments
US5120758A (en) 1991-02-08 1992-06-09 Ciba-Geigy Corporation Certain benzodioxole, benzodioxane and benzodioxepin derivatives useful as 5-lipoxygenase inhibitors
GB9104890D0 (en) 1991-03-08 1991-04-24 Glaxo Group Ltd Compositions
AU651244B2 (en) 1991-09-19 1994-07-14 Mcneilab, Inc. Process for the preparation of chlorosulfate and sulfamate derivatives of 2,3:4,5-bis-0-(1-methylethylidene)-beta-D- fructopyranose and (1-methylcyclohexyl)methanol
US5242942A (en) 1992-04-28 1993-09-07 Mcneilab, Inc. Anticonvulsant fructopyranose cyclic sulfites and sulfates
US5258402A (en) 1992-06-11 1993-11-02 Mcneil-Ppc, Inc. Imidate derivatives of pharmaceutically useful anticonvulsant sulfamates
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5384327A (en) 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates
US5391199A (en) 1993-07-20 1995-02-21 Biosense, Inc. Apparatus and method for treating cardiac arrhythmias
US5499628A (en) 1993-08-27 1996-03-19 Micron Medical Products, Inc. Medical electrode
NZ277725A (en) 1993-12-23 1998-04-27 Ortho Pharma Corp Pseudofructopyranose sulphamate derivatives, preparation and pharmaceutical compositions thereof
DE4417200C1 (de) 1994-05-17 1995-06-22 Hewlett Packard Gmbh Klemmkontaktverbindung
GB9417532D0 (en) 1994-08-31 1994-10-19 Zeneca Ltd Aromatic compounds
US6690963B2 (en) 1995-01-24 2004-02-10 Biosense, Inc. System for determining the location and orientation of an invasive medical instrument
DE69614835T2 (de) 1995-02-15 2002-04-25 Annovis, Inc. Alkylcarboxy-aminosäure modulatoren für den kainat-rezeptor
JP3235448B2 (ja) 1995-03-24 2001-12-04 ダイソー株式会社 １，４−ベンゾジオキサン誘導体の製法
US5998380A (en) 1995-10-13 1999-12-07 New England Medical Center Hospitals, Inc. Treatment of migraine
AU1328197A (en) 1995-12-01 1997-06-19 Synaptic Pharmaceutical Corporation Aryl sulfonamide and sulfamide derivatives and uses thereof
US5782761A (en) 1996-01-24 1998-07-21 Graphic Controls Corporation Molded electrode
CA2250042A1 (en) 1996-03-25 1997-10-02 Eli Lilly And Company Treating pain using a synergistic combination of an atypical antipsychotic and a drug used in treatment of pain
ES2184127T3 (es) 1996-06-28 2003-04-01 Ortho Mcneil Pharm Inc Derivados de sulfamato anticonvulsivos utiles para el tratamiento de la obesidad.
US5753694A (en) 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS)
WO1998000124A1 (en) 1996-06-28 1998-01-08 Ortho Pharmaceutical Corporation Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of postischemic neurodegeneration
US5753693A (en) 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder
NZ334132A (en) 1996-08-14 2000-06-23 G Crystalline form of 4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonamide
JP2001500121A (ja) 1996-08-23 2001-01-09 アルゴス ファーマシューティカル コーポレーション 神経障害性の痛みを治療する組成物を含む抗けいれん剤
US20020015713A1 (en) 1996-10-24 2002-02-07 Murdock Robert W. Methods and transdermal compositions for pain relief
US5935933A (en) 1997-07-16 1999-08-10 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating neuropathic pain
US5760007A (en) 1997-07-16 1998-06-02 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating neuropathic pain
AU9021298A (en) 1997-08-15 1999-03-08 Carolyn Ann Fairbanks Agmatine as a treatment for neuropathic pain
US5978693A (en) 1998-02-02 1999-11-02 E.P. Limited Apparatus and method for reduction of motion artifact
GB9803536D0 (en) 1998-02-19 1998-04-15 Black James Foundation Histamine H,receptor ligands
UA65607C2 (uk) 1998-03-04 2004-04-15 Орто-Макнейл Фармацевтикал, Інк. Фармацевтична композиція (варіанти) та спосіб її приготування
DK72798A (da) 1998-05-28 1998-05-28 Novo Nordisk As Treatment of GABA-uptake related disorders
WO2000001376A2 (en) 1998-07-02 2000-01-13 Eisai Co., Ltd Pharmaceutical compositions and their uses for treatment of demyelinating disorders
US6541520B1 (en) 1998-08-05 2003-04-01 Brookhaven Science Associates Treatment of addiction and addiction-related behavior
US6475043B2 (en) 1998-11-25 2002-11-05 Antaya Technologies Corporation Circular electrical connector
WO2000042996A2 (en) 1999-01-19 2000-07-27 Ortho-Mcneil Pharmaceutical, Inc. Use of anticonvulsant derivatives for treating cluster headaches
WO2000042995A2 (en) 1999-01-21 2000-07-27 Ortho-Mcneil Pharmaceutical, Inc. Use of anticonvulsant derivatives for treating transformed migraine
WO2000050020A2 (en) 1999-02-24 2000-08-31 University Of Cincinnati Use of sulfamate derivatives for treating impulse control disorders
AU3898700A (en) 1999-03-15 2000-10-04 John Claude Krusz Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages
US6583172B1 (en) 1999-04-08 2003-06-24 Richard P. Shank Anticonvulsant derivatives useful in treating chronic neurodegenerative disorders
MXPA01010218A (es) 1999-04-08 2002-03-27 Johnson & Johnson Derivados anticonvulsivos utiles para disminuir lipidos.
JP2003530300A (ja) 1999-04-08 2003-10-14 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 体重低下を維持することに有用な抗痙攣薬誘導体
NZ514811A (en) 1999-04-08 2005-01-28 Ortho Mcneil Pharm Inc Anticonvulsant derivatives useful in reducing blood glucose levels
ATE275950T1 (de) 1999-05-04 2004-10-15 Keith R Edwards Intravenösen verabreichung von valproat zur behandlung von migränekopfschmerzen
DK1187603T3 (da) 1999-06-14 2007-12-17 Vivus Inc Kombinationsterapi tl at bevirke vægttab og at behandle obesitet
AU782759B2 (en) 1999-08-20 2005-08-25 Ortho-Mcneil Pharmaceutical, Inc. Composition comprising a tramadol material and an anticonvulsant drug
FR2803848B1 (fr) 2000-01-19 2002-02-15 Adir Nouveaux derives de benzenesulfonamide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6322503B1 (en) 2000-02-17 2001-11-27 G. Roger Sparhawk, Jr. Method of diagnosing, tracking, and treating depression
US20010036943A1 (en) 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
JP3887796B2 (ja) 2000-04-13 2007-02-28 日本光電工業株式会社 生体用電極
CN101404993A (zh) 2000-07-07 2009-04-08 奥索-麦克尼尔药品公司 用于预防ii型糖尿病和x综合征的发展的抗惊厥剂衍生物
DE10035227A1 (de) 2000-07-20 2002-01-31 Solvay Pharm Gmbh Verfahren zum Auffinden von Verbindungen, welche zur Behandlung und/oder Prophylaxe von Fettleibigkeit geeignet sind
AU2001280865A1 (en) 2000-08-02 2002-02-13 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful for the treatment of depression
US7256184B2 (en) 2000-10-16 2007-08-14 Rodriguez Victorio C Treatment of aging disorders in humans
US6852738B2 (en) 2001-01-30 2005-02-08 Merck & Co., Inc. Acyl sulfamides for treatment of obesity, diabetes and lipid disorders
JP2004536071A (ja) 2001-05-25 2004-12-02 クイーンズ　ユニバーシティ　アット　キングストン 複素環ベータアミノ酸およびそれらの抗癲癇誘発剤としての使用
US20030100594A1 (en) 2001-08-10 2003-05-29 Pharmacia Corporation Carbonic anhydrase inhibitor
US6559293B1 (en) 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
DE10225621B3 (de) 2002-06-07 2004-01-22 Nicolay Verwaltungs-Gmbh Vorrichtung zum elektrischen Verbinden einer Anschlußleitung mit einer Elektrode, insbesondere einer medizintechnischen Hautelektrode
US8637512B2 (en) 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
CH695541A5 (fr) 2002-08-22 2006-06-30 Compex Medical Sa Ensemble de fixation pour électrode biomédicale.
WO2004052190A1 (en) 2002-12-10 2004-06-24 Koninklijke Philips Electronics N.V. A wearable device for bioelectrical interaction with motion artifact correction means
RU2246727C2 (ru) 2003-02-12 2005-02-20 Санкт-Петербургский научно-исследовательский психоневрологический институт им. В.М. Бехтерева (НИПИ) Способ диагностики доклинической стадии эпилепсии
RU2226357C1 (ru) 2003-02-12 2004-04-10 Санкт-Петербургский научно-исследовательский психоневрологический институт им. В.М.Бехтерева Способ диагностики эпилепсии у пациентов с доклинической стадией болезни
AU2004231070B2 (en) 2003-04-10 2008-02-14 Amgen, Inc. Bicyclic compounds having bradykinin receptors affinity and pharmaceutical compositions thereof
JP4373343B2 (ja) 2003-04-16 2009-11-25 スミスクライン・ビーチャム・コーポレイション ペプチドデホルミラーゼ阻害剤
JPWO2004093912A1 (ja) 2003-04-23 2006-07-13 協和醗酵工業株式会社 好中球性炎症疾患の予防および／または治療剤
GB0309781D0 (en) 2003-04-29 2003-06-04 Glaxo Group Ltd Compounds
US6949518B1 (en) 2003-06-25 2005-09-27 Pao-Hsien Chu Methods for treating macular degeneration with topiramate
CN1845914A (zh) 2003-09-02 2006-10-11 默克公司 用于治疗眼压过高的眼用组合物
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
TW200612905A (en) * 2004-06-16 2006-05-01 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
WO2006010008A1 (en) 2004-06-22 2006-01-26 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives for modulation of calcium channels
CA2572833C (en) 2004-07-28 2013-04-09 Janssen Pharmaceutica N.V. Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
US20060276528A1 (en) 2004-08-24 2006-12-07 Abdel-Magid Ahmed F Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents
CA2578407A1 (en) 2004-08-24 2006-03-02 Janssen Pharmaceutica N.V. Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents
EP1831204A4 (en) 2004-12-16 2009-10-21 Kosan Biosciences Inc COMPOUNDS AMBRUTICINE VS
AU2006239930A1 (en) 2005-04-22 2006-11-02 Wyeth Benzodioxane and benzodioxolane derivatives and uses thereof
EP1881959A1 (en) 2005-05-20 2008-01-30 Janssen Pharmaceutica N.V. Process for preparation of sulfamide derivatives
US7536218B2 (en) 2005-07-15 2009-05-19 Biosense Webster, Inc. Hybrid magnetic-based and impedance-based position sensing
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US20070155827A1 (en) 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US20070155824A1 (en) 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US20070155823A1 (en) 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US8492431B2 (en) 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US20070191461A1 (en) 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of migraine
US20070191459A1 (en) 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for Lowering Lipids and Lowering Blood Glucose Levels
US20070191474A1 (en) 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
US20070191460A1 (en) 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Disease Modification / Epileptogenesis
US20070191450A1 (en) 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Mania and Bipolar Disorder
US20070191452A1 (en) 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of pain
US20070191449A1 (en) 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Depression
US20070191451A1 (en) 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives as neuroprotective agents
US20070191453A1 (en) 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of substance abuse and addiction
TW200738669A (en) 2006-02-22 2007-10-16 Janssen Pharmaceutica Nv Crystalline forms of N-(benzo[b]thien-3-ylmethyl)-sulfamide
JP2009537635A (ja) 2006-05-19 2009-10-29 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 癲癇の処置のための共同−療法
US20070293476A1 (en) 2006-05-19 2007-12-20 Smith-Swintosky Virginia L Co-therapy for the treatment of epilepsy and related disorders
US20090182141A1 (en) 2008-01-07 2009-07-16 Ahmed Abdel-Magid Process for the preparation of sulfamide derivatives
US20090247618A1 (en) 2008-03-26 2009-10-01 Ballentine Scott A Process for preparation of benzo-fused heteroaryl derivatives
EA201071121A1 (ru) * 2008-03-26 2011-04-29 Янссен Фармацевтика, Н.В. Способ получения бензопроизводных диоксина
KR20100126535A (ko) 2008-03-26 2010-12-01 얀센 파마슈티카 엔.브이. 벤조-융합된 헤테로아릴 설파메이트의 제조방법 및 ｎ-(((2ｓ)-6-클로로-2,3-다이하이드로-1,4-벤조다이옥신-2-일)메틸-설파미드의 결정형
US20090247617A1 (en) 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
BRPI0915890A2 (pt) 2008-06-23 2015-11-03 Janssen Pharmaceutica Nv forma cristalina de (2s)-(-)-n-(6-cloro-2,3-di-hidro-benzo[1,4]dioxin-2-ilmetil)-sulfamida
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives

Also Published As

Publication number Publication date
EP2340246A2 (en) 2011-07-06
HN2010002735A (es) 2014-07-31
MX2011000090A (es) 2011-03-02
TW201012807A (en) 2010-04-01
NZ590682A (en) 2012-09-28
WO2010008776A2 (en) 2010-01-21
BRPI0915890A2 (pt) 2015-11-03
EA201170079A1 (ru) 2011-06-30
WO2010008776A3 (en) 2011-04-07
NI201000226A (es) 2011-08-01
AU2009271362A1 (en) 2010-01-21
AR072961A1 (es) 2010-10-06
EA018567B1 (ru) 2013-08-30
ZA201100570B (en) 2012-06-27
JP2012530682A (ja) 2012-12-06
CA2729056A1 (en) 2010-01-21
CL2010001540A1 (es) 2011-09-23
UY31934A (es) 2010-01-05
AU2009271362B2 (en) 2014-03-13
PE20110060A1 (es) 2011-01-31
ECSP10010707A (es) 2011-01-31
US8809385B2 (en) 2014-08-19
IL210138A0 (en) 2011-03-31
WO2010008776A9 (en) 2011-02-10
AU2009271362A2 (en) 2011-05-19
US20090318544A1 (en) 2009-12-24
CR20110042A (es) 2011-07-06

Similar Documents

Publication Publication Date Title
CO6341554A2 (es) Forma cristalina de (2s)-(-)-n-(6-cloro-2,3-dihidro-benzo(1,4)dioxin-2-ilmetil)-sulfamida.
UY32000A (es) Derivados novedosos de sulfamidas sustituidas
AR061968A1 (es) Ester isopropilico del acido 4-[5-metoxi-6-(2-metil-6-[1,2,4]triazol-i-il-piridin-3-il-amino)-pirimidin-4-iloxi]-piperidin-i-carboxilico, composicion farmaceutica que lo comprende y un metodo de preparacion de la misma y el uso de este compuesto para el tratamiento de trastornos metabolicos
CU20060153A7 (es) Nueva forma cristalina v de agomelatina, procedimiento para su preparación y composiciones farmacéuticas que las contienen
UY28862A1 (es) Nuevas composiciones farmaceuticas para el tratamiento de los trastornos sexuales ii
CL2008000806A1 (es) Compuestos derivados de aza piridopirimidinona, con actividad agonista de hm74a; procedimiento de preparacion de dichos compuestos; composicion farmaceutico que las comprende; y su uso para preparar medicamentos para el tratamiento de enferemedades ateroscleroticas, dislipidemias, alzheimer, diabetes, entre otras.
CL2007003263A1 (es) Compuestos derivados de 1,4-benzotiepina 1,1-dioxido; producto farmaceutico; procedimiento de preparacion; y uso para el tratamiento de trastornos del metabolismo de lipidos, hiperlipidemia, resistencia a la insulina, diabetes y trastornos del snc, e
UY29248A1 (es) Indoles sustituidos, composiciones que los contienen, procedimiento de fabricación y utilización
PE20070333A1 (es) Composicion farmaceutica que comprende agomelatina para el tratamiento de transtornos del sueno en pacientes deprimidos
UY31554A1 (es) Nuevos inhibidores de acetil coenzima a carboxilasa y usos en tratamientos de obesidad y diabetes mellitus
UY29065A1 (es) Derivados del ácido alcanoico arilcicloalquil-sustituidos, procedimientos para su preparación y su uso como productos farmacéuticos.
CL2012001972A1 (es) Compuestos derivados de oxazol[5,4-d]pirimidina sustituidas; procedimiento de preparacion; composicion farmaceutica; utiles en el tratamiento de trastornos en la curacion de heridas en pacientes con diabetes.
CL2011000184A1 (es) Compuestos derivados de 1,6-dihidro-2h-3-oxa-6-aza-as-indaceno; agonista de receptores de melatonina; proceso para la preparacion de los compuestos; composicion farmaceutica que comprende a los compuestos; y su uso de los compuestos en la preparacion de medicamentos.
CL2008002414A1 (es) Compuestos derivados de tetrahidronaftalenos sustituidos, composicion farmaceutica que comprende dichos compuestos, proceso de preparacion de dicha composicion y uso de los compuestos para tratar y/o prevenir trastornos del metabolismo de acidos grasos y trastornos de la utilizacion de la glucosa.
CR7271A (es) Formulaciones farmaceuticas novedosas a base de melatonina y compuestos similares para su uso en transtornos del sueno
UY31522A1 (es) Nanoparticulas con superficie modificada
GT200800235A (es) Formulacion de medicamento liquida
CL2008002289A1 (es) Compuestos derivados de n-heteroaril-carboxamidas triciclicas; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para tratar dolor, inflamacion, trastornos metabolicos, trastornos urologicos, entre otros.
CL2008002465A1 (es) Composición farmacéutica anhidra tópica, que comprende derivados de niacina y un portador aceptable, su aplicacón permite un bienestar sexual mejorado.
CL2008002163A1 (es) Derivados de 2-azetidina y 2-pirrolidina metanoaminas; sus procesos de obtencion; la composicion farmaceutica que los contienen; y sus usos.
UY28370A1 (es) Agentes terapéuticos
BRPI0515811A (pt) indóis substituìdos, processo para preparação, bem como utilização dos mesmos, medicamento e composição farmacêutica
AR063530A1 (es) Procedimiento de utilizacion de enoxaparina sodica para la preparacion de un medicamento
UY29688A1 (es) Nueva forma cristalina v de la agomelatina, su procedimiento de preparación y las composiciones farmaceuticas que la contienen
AR063816A1 (es) Composicion farmaceutica que comprende ciclobenzaprina y aceclofenac en asociacion

Legal Events

Date Code Title Description
FC Application refused